A recent systematic review and network meta-analysis commissioned by the American College of Physicians showed that, compared with DPP4 inhibitors, SGLT2 inhibitors significantly reduced all-cause mortality, the risk of cardiovascular events, the progression of chronic kidney disease, and hospitalizations for heart failure [13]. This evidence concerns the gene DPP4 and heart failure.